Business
Dario Presents Four Studies at American Diabetes Association Scientific Sessions Highlighting Commercial and Clinical Value of its Digital Health Platform
DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in global digital health, today announced presentation of four studies at the American Diabetes Association's ("ADA") Scientific Sessions highlighting the clinical and economic value of sustained engagement on its platform across high-risk cardiometabolic populations.
About this update from Dariohealth Corp.
Data from a total of 27 studies presented at ADA over 8 years reinforce Dario's strategic move closer to care, expanding revenue model into claims-based and outcomes-driven payments serving health plans, employers and other enterprise buyers Weight loss of 6.4% with Dario alone, and 14.3% when combined with a GLP-1 at 12 months, exceeding benchmarks based on medications alone 44.8% of high-risk diabetes users achieved at least a 1% eA1c reduction at 12 months NEW YORK, June 8, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in global digital health, today announced presentation of four studies at the American Diabetes Association's ("ADA") Scientific Sessions highlighting the clinical and economic value of sustained engagement on its platform across high-risk cardiometabolic populations. Taken together, the studies reinforce a clear commercial message for payers, employers and other enterprise buyers: when high-risk members stay engaged with Dario's platform, outcomes improve in ways that can translate into lower cost of care, stronger member retention and greater long-term value. Across the four studies, Dario observed meaningful reductions in inpatient utilization among high-risk members with diabetes, hypertension and obesity, strong weight outcomes with and without GLP-1 therapy, improved glycemic control and a clear link between consistent engagement and better results. The findings support Dario's core enterprise thesis: sustained engagement in a single cardiometabolic digital platform can produce measurable clinical improvement across overlapping chronic conditions, while reducing avoidable utilization and the cost and complexity of managing multiple point solutions. The growing body of data including 27 studies presented at the ADA alone over the past eight years supports Dario's next strategic growth phase moving closer to care--demonstrating the platform's impact on clinical outcomes and positioning the Company to participate in the medical spend associated with those outcomes. Among the findings, when compared with the control group, participants experienced 0.23 fewer hospitalizations per patient per year ("PPPY"), highlighting Dario's potential to reduce acute healthcare utilization. In a...